Loratadine approvals
This article was originally published in The Tan Sheet
Executive Summary
Wyeth Consumer Care's ANDA 75-822 for orally disintegrating 10 mg loratadine tablets (equivalent to Schering-Plough's Claritin RediTabs) approved by FDA Feb. 10 with180 days of marketing exclusivity. Wyeth already markets the same product under the brand name Alavert, which was approved under a 505(b)(2) application in December (1"The Tan Sheet" Dec. 23, 2002, p. 5). Separately, Andrx's ANDA 75-706 for loratadine 10 mg/pseudoephedrine 240 mg combination, approved Feb. 21, also receives 180-day exclusivity. Andrx will supply Perrigo with the product, which plans to ship the Claritin-D 24-Hour equivalent in mid-June (2"The Tan Sheet" Feb. 3, 2003, p. 13)...
You may also be interested in...
Perrigo Loses Acetaminophen Supplier, Gains Loratadine Deal
The loss of a supplier could cost Perrigo up to $18 mil. in acetaminophen product sales in fiscal year 2004, the private labeler said
Wyeth Alavert Approval Sparks Loratadine Price Wars, Fight For OTC Share
Wyeth Consumer Healthcare is staking a claim to the OTC loratadine market with Alavert pricing of 56¢ to $1 per orally disintegrating tablet and high-value coupons
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.